AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.
Caenepeel, S., Brown, S.P., Belmontes, B., Moody, G., Keegan, K.S., Chui, D., Whittington, D.A., Huang, X., Poppe, L., Cheng, A.C., Cardozo, M., Houze, J., Li, Y., Lucas, B., Paras, N.A., Wang, X., Taygerly, J.P., Vimolratana, M., Zancanella, M., Zhu, L., Cajulis, E., Osgood, T., Sun, J., Damon, L., Egan, R.K., Greninger, P., McClanaghan, J.D., Gong, J., Moujalled, D., Pomilio, G., Beltran, P., Benes, C.H., Roberts, A.W., Huang, D.C., Wei, A., Canon, J., Coxon, A., Hughes, P.E.
Cancer Discov